Published in Medical Letter on the CDC and FDA, December 28th, 2003
Genta recently received approval from the Food and Drug Administration to market Ganite (gallium nitrate injection) for the treatment of cancer-related hypercalcemia that is resistant to hydration. Ganite is the first drug from Genta to receive marketing approval.
Through GentaCARES, HealthBridge answers questions from patients and physicians' offices about insurance coverage. The goal is to simplify the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.